Lewis Cohen
About
Lewis Cohen is a scholar working on Oncology, Molecular Biology and Hematology.
According to data from OpenAlex, Lewis Cohen has authored 41 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 14 papers in Molecular Biology and 10 papers in Hematology. Recurrent topics in Lewis Cohen's work include Multiple Myeloma Research and Treatments (9 papers), Chemokine receptors and signaling (8 papers) and CAR-T cell therapy research (7 papers). Lewis Cohen is often cited by papers focused on Multiple Myeloma Research and Treatments (9 papers), Chemokine receptors and signaling (8 papers) and CAR-T cell therapy research (7 papers). Lewis Cohen collaborates with scholars based in United States, Spain and Germany. Lewis Cohen's co-authors include Vassilios I. Avramis, Michael L. Howe, Antonia Periclou, Pina M. Cardarelli, Harland N. Sather, Janet Franklin, Paul S. Gaynon, Lawrence J. Ettinger, Michelle Kuhne and Alice G. Ettinger and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.
In The Last Decade
Lewis Cohen
40 papers receiving 1.9k citations
Peers
Lewis Cohen
Barbara De Moerloose Belgium
WD Ludwig Germany
Andrew C. Harris United States
Nicola Goekbuget Germany
Tanya Trippett United States
H. Behrendt Netherlands
Fumio Bessho Japan
Massimiliano Bonifacio Italy
Cristina Papayannidis Italy
Angela Michelutti Italy
Citations per year, relative to Lewis Cohen Lewis Cohen (= 1×)
peers
Barbara De Moerloose
Countries citing papers authored by Lewis Cohen
Since
Specialization
Citations
This map shows the geographic impact of Lewis Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lewis Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lewis Cohen more than expected).
Fields of papers citing papers by Lewis Cohen
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Lewis Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lewis Cohen. The network helps show where Lewis Cohen may publish in the future.
Co-authorship network of co-authors of Lewis Cohen
This figure shows the co-authorship network connecting the top 25 collaborators of Lewis Cohen. A scholar is included among the top collaborators of Lewis Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lewis Cohen. Lewis Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Owonikoko, Taofeek K., Arif Hussain, Walter M. Stadler, et al.. (2015). First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemotherapy and Pharmacology. 77(1). 155–162.
2.
Peethambaram, Prema P., Lynn C. Hartmann, Derek J. Jonker, et al.. (2014). A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Investigational New Drugs. 33(2). 321–331.
3.
Choueiri, Toni K., Mayer Fishman, Bernard Escudier, et al.. (2014). Immunomodulatory Activity of Nivolumab in Previously Treated and Untreated Metastatic Renal Cell Carcinoma (Mrcc): Biomarker-Based Results from a Randomized Clinical Trial. Annals of Oncology. 25. iv362–iv362.
4.
Owonikoko, Taofeek K., Arif Hussain, Walter M. Stadler, et al.. (2014). A phase 1 multicenter open-label dose-escalation study of BMS-936561 (MDX-1203) in clear cell renal cell carcinoma (ccRCC) and B-cell non Hodgkin lymphoma (B-NHL).. Journal of Clinical Oncology. 32(15_suppl). 2558–2558.
5.
Chow, Laura Q.M., Michael S. Gordon, Theodore F. Logan, et al.. (2013). Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors.. Journal of Clinical Oncology. 31(15_suppl). TPS3112–TPS3112.
6.
Godwin, John E., Izidore S. Lossos, Michael E. Williams, et al.. (2013). A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies.. Journal of Clinical Oncology. 31(15_suppl). TPS3108–TPS3108.
7.
Chien, Sylvia, Brent L. Wood, Elihu H. Estey, et al.. (2013). Mobilization Of Blasts and Leukemia Stem Cells by Anti-CXCR4 Antibody BMS-936564 (MDX 1338) in Patients With Relapsed/Refractory Acute Myeloid Leukemia. Blood. 122(21). 3882–3882.
8.
Kuhne, Michelle, Chin Pan, Fei Cao, et al.. (2012). BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies. Clinical Cancer Research. 19(2). 357–366.
9.
Roccaro, Aldo M., Antonio Sacco, Michelle Kuhne, et al.. (2012). CXCR4 Monoclonal Antibody, BMS-936564 (MDX-1338), Modulates Epithelial to Mesenchymal Transition (EMT) in Multiple Myeloma Cells. Blood. 120(21). 4009–4009.
10.
Kuhne, Michelle, Chin Pan, Karla A. Henning, et al.. (2009). Abstract #LB-150: A fully human anti-CXCR4 antibody induces apoptosis in vitro and shows anti tumor activity in vivo.. Cancer Research. 69.
11.
Panosyan, Eduard H., Nita L. Seibel, Sagrario Martín‐Aragón, et al.. (2004). Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology. 26(4). 217–226.
12.
Bukowski, Ronald M., et al.. (2003). A Phase I–II trial of polyethylene glycol‐conjugated L‐asparaginase in patients with multiple myeloma. Cancer. 98(1). 94–99.
13.
Cushing, Barbara, Roger Giller, Arthur R. Ablin, et al.. (2000). Surgical Resection Alone Is Effective Treatment for Ovarian Immature Teratoma in Children and Adolescents: A Report of the Pediatric Oncology Group and the Children’s Cancer Group. Obstetrical & Gynecological Survey. 55(1). 29–29.
14.
Cushing, Barbara, Roger Giller, Arthur R. Ablin, et al.. (1999). Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: A report of the Pediatric Oncology Group and the Children’s Cancer Group. American Journal of Obstetrics and Gynecology. 181(2). 353–358.
15.
Belani, Chandra P., Philip Bonomi, Russell F. DeVore, et al.. (1999). Docetaxel and Cisplatin in Patients with Advanced Non–Small-Cell Lung Cancer (NSCLC): A Multicenter Phase II Trial. Clinical Lung Cancer. 1(2). 144–150.
16.
Avramis, Vassilios I., et al.. (1998). Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells.. PubMed. 18(4A). 2327–38.
17.
Cohen, Lewis, Nancy B. McWilliams, William H. Zinkham, et al.. (1995). Prophylaxis and therapy with factor VII concentrate (human) immuno, vapor heated in patients with congenital factor VII deficiency: A summary of case reports. American Journal of Hematology. 50(4). 269–276.
18.
Cohen, Lewis, Sheila Sharp, & Anthony Kulczycki. (1983). Human monocytes, B lymphocytes, and non-B lymphocytes each have structurally unique Fc gamma receptors.. The Journal of Immunology. 131(1). 378–383.
19.
Howe, Michael L. & Lewis Cohen. (1975). Lymphoid cell subpopulations. I. Synergy between lymph node cells and thymocytes in response to alloantigens and mitogens.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 115(5). 1227–32.
20.
Howe, Michael L., et al.. (1973). Relationship between Proliferative and Effector Phases of the Mixed Lymphocyte Reaction and Graft-Vs-Host Reaction. The Journal of Immunology. 111(4). 1243–1249.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Barbara De Moerloose Breakdown of academic impact, for papers by WD Ludwig Breakdown of academic impact, for papers by Andrew C. Harris Breakdown of academic impact, for papers by Nicola Goekbuget Breakdown of academic impact, for papers by Tanya Trippett Breakdown of academic impact, for papers by H. Behrendt Breakdown of academic impact, for papers by Fumio Bessho Breakdown of academic impact, for papers by Massimiliano Bonifacio Breakdown of academic impact, for papers by Cristina Papayannidis Breakdown of academic impact, for papers by Angela Michelutti